Foluso O Ademuyiwa

List of Publications by Year
in descending order

53	3,301	186265 28	197818 49
papers	citations	h-index	g-index

56	56	56	7099
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 550-562.	6.4	48
2	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. Surgical Oncology Clinics of North America, 2022, 31, 109-126.	1.5	9
3	Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i). Cancer Research, 2022, 82, P2-07-01-P2-07-01.	0.9	0
4	A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. Npj Breast Cancer, 2022, 8, 35.	5.2	7
5	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. Breast Cancer: Targets and Therapy, 2022, Volume 14, 113-123.	1.8	10
6	Racial differences in noâ€show rates for screening mammography. Cancer, 2021, 127, 1857-1863.	4.1	11
7	ImmunogenomicÂprofiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 187-202.	2.5	24
8	Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. Journal of Clinical Oncology, 2021, 39, 4020-4028.	1.6	20
9	Characteristics of male triple negative breast cancer: A populationâ€based study. Breast Journal, 2020, 26, 1748-1755.	1.0	5
10	Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine, 2020, 59, 102963.	6.1	63
11	Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 288-296.	4.9	13
12	Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. Breast Cancer Research and Treatment, 2019, 178, 151-159.	2.5	17
13	Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLoS ONE, 2019, 14, e0222358.	2.5	35
14	Updates on Molecular Classification of Triple Negative Breast Cancer. Current Breast Cancer Reports, 2018, 10, 289-295.	1.0	1
15	Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging. Journal of Biomedical Optics, 2018, 24, 1.	2.6	46
16	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2017, 23, 4055-4065.	7.0	243
17	Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Research and Treatment, 2017, 161, 491-499.	2.5	59
18	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or IIIPIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	7.0	66

#	Article	IF	Citations
19	Managing breast cancer in younger women: challenges and solutions. Breast Cancer: Targets and Therapy, 2016, 8, 1.	1.8	20
20	Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound. Journal of the American College of Surgeons, 2016, 223, 399-407.	0.5	30
21	Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. Annals of Surgery, 2016, 264, 1098-1102.	4.2	53
22	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer, 2016, 16, 471-479.e1.	2.4	29
23	Comparative Effectiveness of Biomarkers to Target Cancer Treatment. Medical Decision Making, 2016, 36, 594-603.	2.4	2
24	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptorâ€“Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 1583-1591.	7.0	86
25	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
26	US breast cancer mortality trends in young women according to race. Cancer, 2015, 121, 1469-1476.	4.1	43
27	Reply to differences in 25â€hydroxyvitamin D concentrations may explain most of the blackâ€white breast cancer disparities noted in young women. Cancer, 2015, 121, 2098-2098.	4.1	0
28	CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 2473-2485.	4.1	51
29	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
30	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
31	Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Research and Treatment, 2013, 138, 241-248.	2.5	29
32	Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer. Journal of Oncology, 2013, 2013, 1-8.	1.3	15
33	19p13.1 Is a Triple-Negativeâ€“Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
34	Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Modern Pathology, 2012, 25, 388-397.	5.5	69
35	Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Research, 2012, 14, R58.	5.0	75
36	An 81-Year-Old Patient With Distant Metastasis of Invasive Lobular Carcinoma Occurring 41 Years After Mastectomy. Clinical Breast Cancer, 2012, 12, 293-295.	2.4	2

#	Article	IF	Citations
37	Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. Journal of Geriatric Oncology, 2012, 3, 320-328.	1.0	12
38	Importance of Biosy of a Presumed Solitary Skeletal Metastasis: Enchondroma in a Breast Cancer Patient. Breast Journal, 2012, 18, 172-174.	1.0	0
39	Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology, 2012, 61, 365-377.	2.9	44
40	NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer. PLoS ONE, 2012, 7, e38783.	2.5	85
41	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
42	The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Research and Treatment, 2011, 126, 797-802.	2.5	99
43	Impact of body mass index on clinical outcomes in tripleâ€negative breast cancer. Cancer, 2011, 117, 4132-4140.	4.1	86
44	ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Modern Pathology, 2011, 24, 1055-1059.	5.5	9
45	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
46	Breast Cancer Racial Disparities: Unanswered Questions. Cancer Research, 2011, 71, 640-644.	0.9	64
47	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Modern Pathology, 2010, 23, 270-275.	5.5	43
48	Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Modern Pathology, 2010, 23, 1364-1378.	5.5	21
49	The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2009, 21, 110-115.	2.4	14
50	Incorporation of Antiangiogenic Therapies in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer, 2008, 8, S151-S156.	2.4	13
51	Cetuximab in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2008, 8, 107-113.	3.1	1
52	Prognostic Factors in Stage III Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, 478-482.	2.6	47
53	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. JAMA - Journal of the American Medical Association, 2005, 294, 1925.	7.4	219